• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

美国晚期/转移性结直肠癌患者中错配修复/微卫星不稳定(MMR/MSI)检测的经验。

Experience of mismatch repair/microsatellite instability (MMR/MSI) testing among patients with advanced/metastatic colorectal cancer in the US.

机构信息

ICON plc, Stockholm, Sweden.

Merck & Co., Inc, North Wales, PA, USA.

出版信息

Curr Med Res Opin. 2020 Aug;36(8):1355-1361. doi: 10.1080/03007995.2020.1776235. Epub 2020 Jun 16.

DOI:10.1080/03007995.2020.1776235
PMID:32468869
Abstract

We assessed knowledge and awareness of MMR/MSI testing among advanced/metastatic CRC patients in the US who had previously taken the test. A non-interventional, cross-sectional online survey was conducted among 150 US CRC patients invited through a research panel. Eligible patients had to be ≥18 years, with stage III or IV CRC (self-reported), had undergone MMR/MSI testing for CRC in past 12 months and could recall the test, and provided informed consent. Descriptive analyses were performed. 81.3% of patients received MMR/MSI testing information from their doctor. Of 64.7% of patients who were a member of a patient support group, 86.6% received information from their groups. Most patients (82.7%) also searched for information on their own (internet searches). Most patients (93.5 to 96.9%) were satisfied with information received from these sources. Reasons for having testing done included increasing knowledge about their cancer (69.3%), being beneficial to determining treatment options (60.7%), and doctor recommendation (62.7%). Key barriers to testing included personal reservations regarding benefits of the test (29.3%), insurance coverage (27.3%), and out-of-pocket costs (18.7%); 45.3% reported no barriers. Patients were well informed about MMR/MSI testing. Increased education of testing benefits and addressing financial barriers may help to further improve testing rates.

摘要

我们评估了美国既往接受过 MMR/MSI 检测的晚期/转移性 CRC 患者对 MMR/MSI 检测的认知和意识。通过研究小组邀请了 150 名美国 CRC 患者,进行了一项非干预性、横断面在线调查。合格的患者必须年满 18 岁,有 III 期或 IV 期 CRC(自我报告),在过去 12 个月内接受过 CRC 的 MMR/MSI 检测且能够回忆起该检测,并提供了知情同意书。进行了描述性分析。81.3%的患者从医生那里获得 MMR/MSI 检测信息。在 64.7%的参加患者支持小组的患者中,86.6%从他们的小组获得信息。大多数患者(82.7%)还自行搜索信息(互联网搜索)。大多数患者(93.5%至 96.9%)对从这些来源获得的信息感到满意。进行检测的原因包括增加对癌症的了解(69.3%)、对确定治疗方案有益(60.7%)以及医生建议(62.7%)。检测的主要障碍包括对检测益处的个人保留意见(29.3%)、保险覆盖范围(27.3%)和自付费用(18.7%);45.3%的患者报告没有障碍。患者对 MMR/MSI 检测有很好的了解。增加对检测益处的教育和解决财务障碍可能有助于进一步提高检测率。

相似文献

1
Experience of mismatch repair/microsatellite instability (MMR/MSI) testing among patients with advanced/metastatic colorectal cancer in the US.美国晚期/转移性结直肠癌患者中错配修复/微卫星不稳定(MMR/MSI)检测的经验。
Curr Med Res Opin. 2020 Aug;36(8):1355-1361. doi: 10.1080/03007995.2020.1776235. Epub 2020 Jun 16.
2
Mismatch Repair/Microsatellite Instability Testing Practices among US Physicians Treating Patients with Advanced/Metastatic Colorectal Cancer.美国治疗晚期/转移性结直肠癌患者的医生中错配修复/微卫星不稳定性检测实践
J Clin Med. 2019 Apr 24;8(4):558. doi: 10.3390/jcm8040558.
3
DNA mismatch repair and microsatellite instability in colorectal tumors: an observational study in the Veterans Affairs Health Care System.结直肠肿瘤中的 DNA 错配修复和微卫星不稳定性:退伍军人事务医疗保健系统中的观察性研究。
Future Oncol. 2022 Feb;18(6):649-660. doi: 10.2217/fon-2021-0874. Epub 2022 Jan 24.
4
Mismatch repair status between primary colorectal tumor and metastatic tumor, a retrospective consistent study.原发结直肠肿瘤与转移瘤之间错配修复状态的回顾性一致性研究。
Biosci Rep. 2019 Dec 20;39(12). doi: 10.1042/BSR20190730.
5
The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study.错配修复状态在结直肠癌中对辅助化疗治疗决策的影响:一项基于澳大利亚人群的多中心研究。
Oncologist. 2016 May;21(5):618-25. doi: 10.1634/theoncologist.2015-0530. Epub 2016 Mar 23.
6
Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.程序性死亡配体-1检测及免疫疗法在微卫星不稳定的结直肠癌中是否有作用?第一部分——结直肠癌:微卫星不稳定、检测及临床意义
Arch Pathol Lab Med. 2018 Jan;142(1):17-25. doi: 10.5858/arpa.2017-0040-RA. Epub 2017 Nov 16.
7
DNA Mismatch Repair Deficiency Detection in Colorectal Cancer by a New Microsatellite Instability Analysis System.采用新型微卫星不稳定性分析系统检测结直肠癌中 DNA 错配修复缺陷。
Interdiscip Sci. 2020 Jun;12(2):145-154. doi: 10.1007/s12539-020-00358-8. Epub 2020 Jan 25.
8
Clinical Impact of Mismatch Repair Protein Testing on Outcome of Early Staged Colorectal Carcinomas.错配修复蛋白检测对早期结直肠癌预后的临床影响
J Gastrointest Cancer. 2018 Dec;49(4):406-414. doi: 10.1007/s12029-017-9954-5.
9
Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.具有微卫星不稳定性/DNA错配修复缺陷的遗传性和散发性转移性结直肠癌的临床和分子特征
Eur J Cancer. 2017 Nov;86:266-274. doi: 10.1016/j.ejca.2017.09.022. Epub 2017 Oct 19.
10
Molecular analysis of Iranian colorectal cancer patients at risk for Lynch syndrome: a new molecular, clinicopathological feature.伊朗林奇综合征高危结直肠癌患者的分子分析:一种新的分子及临床病理特征。
J Gastrointest Cancer. 2015 Jun;46(2):118-25. doi: 10.1007/s12029-015-9696-1.

引用本文的文献

1
A Focused Clinical Review of Lynch Syndrome.林奇综合征的重点临床综述
Cancer Manag Res. 2023 Jan 18;15:67-85. doi: 10.2147/CMAR.S283668. eCollection 2023.
2
Underutilization of Guideline-Recommended Mismatch Repair/Microsatellite Instability Biomarker Testing in Advanced Colorectal Cancer.指南推荐的错配修复/微卫星不稳定生物标志物检测在晚期结直肠癌中的未充分利用。
Cancer Epidemiol Biomarkers Prev. 2022 Sep 2;31(9):1746-1751. doi: 10.1158/1055-9965.EPI-22-0279.
3
Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer.
晚期胃癌治疗中预测和预后生物标志物的演变。
J Cancer Res Clin Oncol. 2022 Aug;148(8):2023-2043. doi: 10.1007/s00432-021-03902-1. Epub 2022 May 13.